USP Seeks Experts for 2015-2020 Council of Experts - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

USP Seeks Experts for 2015-2020 Council of Experts



The U.S. Pharmacopeial Convention (USP) has announced its call for candidates for the 2015–2020 Council of Experts, USP’s scientific decision-making body.

USP’s Council of Experts is responsible for developing and revising standards that are included in USP’s seven compendia: The United States Pharmacopeia and the National Formulary; Medicines Compendium; USP on Compounding; Herbal Medicines Compendium; Dietary Supplements Compendium; and Food Chemicals Codex.

Currently more than 30% of the Council’s members comprise experts from outside of the US. The 2015–2020 Council of Experts includes 26 Expert Committees, six of which will meet outside of the US. All Expert Committees are supported by USP’s international site and Rockville, Maryland headquarters staff. The 2015–2020 Council of Experts will benefit from USP’s network of laboratories, which includes over 170,000 square feet of laboratory resources and a global staff located in the US, India, China, and Brazil.

The Council of Experts is elected every five years at the meeting of the USP Convention, with the next meeting to take place in April 2015. New experts will begin their five-year tenure on July 1, 2015. Members of the Council of Experts serve as chairs of USP’s Expert Committees, each of which addresses a specific standards-setting area within USP. Theseareas include chemical medicines, biologic medicines, excipients, compounded preparations, dietary supplements, and food ingredients. USP is also seeking candidates to serve as members of Expert Committees.

Candidates may nominate themselves or a colleague at http://uspgo.to/c

Source: USP

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here